Submitral aneurysm (SMA) results from outpouching of the left ventricular wall which is congenital and occurs adjacent to the posterior leaflet of the mitral valve. Although it is predominantly described among the natives of Africa, it is considered rare in the Indian subcontinent. It presents clinically as palpitation, congestive cardiac failure in the presence of mitral regurgitation, arrhythmias and embolic phenomenon. Echocardiography is the precise diagnostic tool. We report this case of a 24-year-old man who was referred for evaluation of palpitation. This underlines the importance of considering SMA in the differential diagnosis of mitral regurgitation in young patients in our subcontinent where rheumatic etiology usually predominates.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295526 | PMC |
http://dx.doi.org/10.14740/cr408w | DOI Listing |
JACC Case Rep
January 2025
Department for Internal Medicine II, Cardiology, Medical University of Vienna, Vienna, Austria.
Mitral and tricuspid regurgitation, linked to high morbidity and mortality, are increasingly treated with interventional edge-to-edge repair, showing excellent results in favorable anatomy. Recently, interventional valve replacement strategies have emerged. We present a patient with severe dyspnea and leg edema who was diagnosed with severe mitral and torrential tricuspid regurgitation.
View Article and Find Full Text PDFJACC Case Rep
January 2025
General Surgery Department, Hospital General Dr Manuel Gea González, Mexico City, Mexico.
A 34-year-old man with sudden palpitations, dyspnea, and chest pain was found to have tachycardia and unilateral pulmonary congestion. Intravenous adenosine restored sinus rhythm. Imaging and pathology confirmed an atrial myxoma with severe mitral regurgitation, requiring surgical excision and mitral valve replacement.
View Article and Find Full Text PDFCASE (Phila)
December 2024
Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
• Redo surgery for severe MR after MA can be high risk. • m-TEER can be successful if patient is not a candidate for redo surgery or valve-in-ring. • Small mitral orifice area and postdevice mean gradient may limit m-TEER to 1 device.
View Article and Find Full Text PDFAnatol J Cardiol
January 2025
Department of Cardiology, Eskişehir Osmangazi University, Eskişehir, Türkiye.
Open Heart
January 2025
The University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada.
Background: Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ongoing controversy regarding optimal anti-thrombotic therapy post-MVr. This scoping review aimed to summarise current evidence on the safety and efficacy of anti-thrombotic therapy after MVr, identify knowledge gaps and propose a future study design.
Methods: We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Clinicaltrials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!